Could a skin cream boost immunotherapy for advanced cancer?
NCT ID NCT05481658
First seen Feb 20, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This early-stage study tests whether a topical cream called diphencyprone (DPCP) can make immunotherapy (PD-1/PD-L1 inhibitors) work better for people with advanced cancer that has spread to the skin. About 100 participants will apply the cream twice a week for 12 weeks alongside their standard immunotherapy. The main goals are to check safety and to see how the treatment changes immune activity in the skin tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Conditions
Explore the condition pages connected to this study.